Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX,…
Harrow, an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, announced that it has entered into…
Read More...
Read More...
